Vertex's next-generation cystic fibrosis drug gets EU approval

Published: 2025-07-01 07:47:11 ET VRTX

Published on 07/01/2025 at 07:47, updated on 07/01/2025 at 07:48

(Reuters) -Vertex said on Tuesday that its next-generation drug, Alyftrek, gained European Commission approval for the treatment of cystic fibrosis.

CF is an inherited disorder resulting from the absence of a specific protein, which disrupts the movement of salt and water in and out of cells in various organs.

(Reporting by Christy Santhosh in Bengaluru; Editing by Tasim Zahid)